One study found that Trm actually increased PGC-1α and transcript abundance of its mitochondrial biogenesis targets in the kidney,(52) but we found no difference in PGC-1α in Trm-treated compared to vehicle-treated hearts (Supplemental Figure S6C) This apparent discrepancy is unsurprising given that mitochondrial physiology differs substantially across somatic cells(53) and cancer cell types.(54). Here, PPARGC1A is linked to cancer.